STR has started a clinical trial in Europe for its ACL device and has successfully implanted the device in 7 patients as of October 2013. Their device utilizes a synthetic scaffold that regenerates the entire ligament tissue resulting in better chances of full recovery.
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.
Orexigen Therapeutics is a biopharmaceutical company that focuses its attention on the treatment of one of the most common diseases in existence today, obesity.
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
Athersys (ATHX) is a clinical stage based biopharmaceutical company with an exponentially growing pipeline and an array of products in therapeutics to treat significant and life-threatening diseases.
A company to keep a look out for in the upcoming future is BioDelivery Sciences International (BDSI), a specialty pharmaceutical company with a platform of drug delivery technologies to develop, commercialize, and improve already proven applications of therapeutics.
Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech.
Novavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world.
Cytokinetics (CYTK) is a clinical stage biotechnology company that focuses on the discovery and development of novel molecular therapeutics in relation to muscle function.
Orexo is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction.
Copyright © 2024 | WordPress Theme by MH Themes